Innovative Therapeutics: Designer Natriuretic Peptides

JACC. Basic to Translational Science
Laura M G Meems, John C Burnett

Abstract

Endogenous natriuretic peptides serve as potent activators of particulate guanylyl cyclase receptors and the second messenger cGMP. Natriuretic peptides are essential in maintenance of volume homeostasis, and can be of myocardial, renal and endothelial origin. Advances in peptide engineering have permitted the ability to pursue highly innovative drug discovery strategies. This has resulted in designer natriuretic peptides that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Together with recent improvements in peptide delivery systems, which have improved bioavailability, further advances in this field have been made. Therefore, designer natriuretic peptides with pleotropic actions together with strategies of chronic delivery have provided an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the natriuretic peptides that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension, which include Cenderitide, ANX042 and ZD100.

References

Oct 1, 1992·European Journal of Clinical Investigation·M KentschG Müller-Esch
Oct 1, 1993·The Journal of Clinical Investigation·C M WeiJ C Burnett
Jul 31, 1998·The New England Journal of Medicine·E R LevinW K Samson
Jul 19, 2002·The New England Journal of Medicine·Alan S MaiselUNKNOWN Breathing Not Properly Multinational Study Investigators
Oct 9, 2002·Congestive Heart Failure·Roger M MillsJames B Young
Jan 4, 2005·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Horng H ChenJohn C Burnett
Feb 26, 2005·Circulation Journal : Official Journal of the Japanese Circulation Society·Mitsuru SuwaKazuteru Funahashi
Mar 22, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Jeetendra B PatelMargaret M Redfield
Mar 23, 2005·Circulation·Jonathan D Sackner-BernsteinKeith D Aaronson
Apr 21, 2005·JAMA : the Journal of the American Medical Association·Jonathan D Sackner-BernsteinKeith Aaronson
May 25, 2005·Peptides·Madhu B Anand-Srivastava
Oct 8, 2005·European Journal of Heart Failure·Cornelia H M van JaarsveldRobbert Sanderman
Feb 22, 2008·The American Journal of Cardiology·Abelardo Martinez-RumayorJames L Januzzi
Jun 3, 2008·American Heart Journal·Hartmut LüssMarkus Meyer
Jun 28, 2008·Journal of the American College of Cardiology·Ondrej LisyJohn C Burnett
Sep 25, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Noritake HataMasahiko Kinoshita
Oct 23, 2008·The Journal of Biological Chemistry·Deborah M DickeyLincoln R Potter
May 22, 2009·The Journal of Biological Chemistry·Deborah M DickeyLincoln R Potter
Jun 23, 2009·Proceedings of the National Academy of Sciences of the United States of America·Shuchong PanRobert D Simari
Apr 5, 2011·Journal of Molecular and Cellular Cardiology·Deborah M Dickey, Lincoln R Potter
Jul 8, 2011·The New England Journal of Medicine·C M O'ConnorR M Califf
Jul 30, 2011·Journal of the American College of Cardiology·Valentina CannoneJohn C Burnett
Dec 3, 2011·Current Hypertension Reports·Paul M McKieJohn C Burnett
Feb 7, 2012·The Journal of Clinical Investigation·Marica BordicchiaSheila Collins
Jul 27, 2012·The New England Journal of Medicine·Thomas J Wang
Oct 13, 2012·Journal of the American College of Cardiology·Fima MacheretAlessandro Cataliotti
Nov 6, 2012·Journal of the American College of Cardiology·Horng H ChenJohn C Burnett
Nov 13, 2012·Lancet·John R TeerlinkUNKNOWN RELAXin in Acute Heart Failure (RELAX-AHF) Investigators
Jul 19, 2013·PloS One·Xu Wen NgSubbu S Venkatraman
Sep 14, 2013·Circulation Research·Steven M Jay, Richard T Lee

❮ Previous
Next ❯

Citations

Dec 1, 2017·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Yang ChenJohn C Burnett
Mar 28, 2018·International Journal of Molecular Sciences·Yang Chen, John C Burnett
Apr 18, 2019·Current Opinion in Cardiology·Jens JordanAlexander Pfeifer
Aug 1, 2018·Expert Review of Endocrinology & Metabolism·Srikanth YandrapalliGregg M Lanier
Aug 3, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Orsolya PéterfiLászló Bába
Mar 29, 2020·European Journal of Heart Failure·Navin SuthaharRudolf A de Boer
May 31, 2019·International Journal of Molecular Sciences·Daniela Maria TanaseMariana Floria
Feb 26, 2019·Hypertension·Laura M G MeemsJohn C Burnett
Jun 17, 2020·Journal of the Endocrine Society·Shravya Vinnakota, Horng H Chen
Dec 21, 2018·Circulation·S Jeson Sangaralingham, John C Burnett
May 1, 2020·Current Cardiology Reviews·Yaniel Castro-Torres, Richard E Katholi
Aug 6, 2018·Mayo Clinic Proceedings·Valentina CannoneJohn C Burnett
Oct 15, 2020·Current Topics in Medicinal Chemistry·Yana LernerNir Qvit
Nov 3, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Speranza Rubattu, Giovanna Gallo
Oct 8, 2021·Circulation Research·Yupeng YanYibo Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modification

Clinical Trials Mentioned

NCT01661634
NCT02603614
NCT01638104

Software Mentioned

MANP

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

© 2022 Meta ULC. All rights reserved